Cargando…

Molecular Mechanism of Epimedium Extract against Ischemic Stroke Based on Network Pharmacology and Experimental Validation

Ischemic stroke exhibits high morbidity, disability, and mortality, and treatments for ischemic stroke are limited despite intensive research. The potent neuroprotective benefits of Epimedium against ischemic stroke have gained lots of interest. Nevertheless, systematic research on the direct role a...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Hongbei, You, Mingyao, Xiang, Xiang, Zhao, Jun, Yuan, Ping, Chu, Lan, Xie, Chenchen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9633197/
https://www.ncbi.nlm.nih.gov/pubmed/36338345
http://dx.doi.org/10.1155/2022/3858314
_version_ 1784824207809445888
author Xu, Hongbei
You, Mingyao
Xiang, Xiang
Zhao, Jun
Yuan, Ping
Chu, Lan
Xie, Chenchen
author_facet Xu, Hongbei
You, Mingyao
Xiang, Xiang
Zhao, Jun
Yuan, Ping
Chu, Lan
Xie, Chenchen
author_sort Xu, Hongbei
collection PubMed
description Ischemic stroke exhibits high morbidity, disability, and mortality, and treatments for ischemic stroke are limited despite intensive research. The potent neuroprotective benefits of Epimedium against ischemic stroke have gained lots of interest. Nevertheless, systematic research on the direct role and mechanisms of Epimedium in ischemic stroke is still lacking. Network pharmacology analysis coupled with experimental verification was utilized to systematically evaluate the potential pharmacological mechanism of Epimedium against ischemic stroke. The TCMSP database was used to mine the bioactive ingredients and Epimedium's targets. The DrugBank, OMIM, and GeneCards databases were employed to identify potential targets of ischemic stroke. GO and KEGG pathway analyses were also carried out. The interaction between active components and hub targets was confirmed via molecular docking. An experimental ischemic stroke model was used to evaluate the possible therapeutic mechanism of Epimedium. As a result, 23 bioactive compounds of Epimedium were selected, and 30 hub targets of Epimedium in its function against ischemic stroke were identified, and molecular docking results demonstrated good binding. The IL-17 signaling pathway was revealed as a potentially significant pathway, with the NF-κB and MAPK/ERK signaling pathways being involved. Furthermore, in vivo experiments demonstrated that Epimedium treatment could improve neurological function and reduce infarct volume. Additionally, Epimedium reduced the activation of microglia and astrocytes in both the ischemic penumbra of the hippocampus and cerebral cortex following ischemic stroke. Western blot and RT–qPCR analyses demonstrated that Epimedium not only depressed the expression of IL-1β, TNF-α, IL-6, and IL-4 but also inhibited the NF-κB and MAPK/ERK signaling pathways. This study applied network pharmacology and in vivo experiment to explore possible mechanism of Epimedium's role against ischemic stroke, which provides insight into the treatment of ischemic stroke.
format Online
Article
Text
id pubmed-9633197
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-96331972022-11-04 Molecular Mechanism of Epimedium Extract against Ischemic Stroke Based on Network Pharmacology and Experimental Validation Xu, Hongbei You, Mingyao Xiang, Xiang Zhao, Jun Yuan, Ping Chu, Lan Xie, Chenchen Oxid Med Cell Longev Research Article Ischemic stroke exhibits high morbidity, disability, and mortality, and treatments for ischemic stroke are limited despite intensive research. The potent neuroprotective benefits of Epimedium against ischemic stroke have gained lots of interest. Nevertheless, systematic research on the direct role and mechanisms of Epimedium in ischemic stroke is still lacking. Network pharmacology analysis coupled with experimental verification was utilized to systematically evaluate the potential pharmacological mechanism of Epimedium against ischemic stroke. The TCMSP database was used to mine the bioactive ingredients and Epimedium's targets. The DrugBank, OMIM, and GeneCards databases were employed to identify potential targets of ischemic stroke. GO and KEGG pathway analyses were also carried out. The interaction between active components and hub targets was confirmed via molecular docking. An experimental ischemic stroke model was used to evaluate the possible therapeutic mechanism of Epimedium. As a result, 23 bioactive compounds of Epimedium were selected, and 30 hub targets of Epimedium in its function against ischemic stroke were identified, and molecular docking results demonstrated good binding. The IL-17 signaling pathway was revealed as a potentially significant pathway, with the NF-κB and MAPK/ERK signaling pathways being involved. Furthermore, in vivo experiments demonstrated that Epimedium treatment could improve neurological function and reduce infarct volume. Additionally, Epimedium reduced the activation of microglia and astrocytes in both the ischemic penumbra of the hippocampus and cerebral cortex following ischemic stroke. Western blot and RT–qPCR analyses demonstrated that Epimedium not only depressed the expression of IL-1β, TNF-α, IL-6, and IL-4 but also inhibited the NF-κB and MAPK/ERK signaling pathways. This study applied network pharmacology and in vivo experiment to explore possible mechanism of Epimedium's role against ischemic stroke, which provides insight into the treatment of ischemic stroke. Hindawi 2022-10-27 /pmc/articles/PMC9633197/ /pubmed/36338345 http://dx.doi.org/10.1155/2022/3858314 Text en Copyright © 2022 Hongbei Xu et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Xu, Hongbei
You, Mingyao
Xiang, Xiang
Zhao, Jun
Yuan, Ping
Chu, Lan
Xie, Chenchen
Molecular Mechanism of Epimedium Extract against Ischemic Stroke Based on Network Pharmacology and Experimental Validation
title Molecular Mechanism of Epimedium Extract against Ischemic Stroke Based on Network Pharmacology and Experimental Validation
title_full Molecular Mechanism of Epimedium Extract against Ischemic Stroke Based on Network Pharmacology and Experimental Validation
title_fullStr Molecular Mechanism of Epimedium Extract against Ischemic Stroke Based on Network Pharmacology and Experimental Validation
title_full_unstemmed Molecular Mechanism of Epimedium Extract against Ischemic Stroke Based on Network Pharmacology and Experimental Validation
title_short Molecular Mechanism of Epimedium Extract against Ischemic Stroke Based on Network Pharmacology and Experimental Validation
title_sort molecular mechanism of epimedium extract against ischemic stroke based on network pharmacology and experimental validation
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9633197/
https://www.ncbi.nlm.nih.gov/pubmed/36338345
http://dx.doi.org/10.1155/2022/3858314
work_keys_str_mv AT xuhongbei molecularmechanismofepimediumextractagainstischemicstrokebasedonnetworkpharmacologyandexperimentalvalidation
AT youmingyao molecularmechanismofepimediumextractagainstischemicstrokebasedonnetworkpharmacologyandexperimentalvalidation
AT xiangxiang molecularmechanismofepimediumextractagainstischemicstrokebasedonnetworkpharmacologyandexperimentalvalidation
AT zhaojun molecularmechanismofepimediumextractagainstischemicstrokebasedonnetworkpharmacologyandexperimentalvalidation
AT yuanping molecularmechanismofepimediumextractagainstischemicstrokebasedonnetworkpharmacologyandexperimentalvalidation
AT chulan molecularmechanismofepimediumextractagainstischemicstrokebasedonnetworkpharmacologyandexperimentalvalidation
AT xiechenchen molecularmechanismofepimediumextractagainstischemicstrokebasedonnetworkpharmacologyandexperimentalvalidation